Postoperative Analgesic Effects of Dexmedetomidine for Transversus Abdominis Plane Block

Pain Clinical Trial

— TAP  

Official title:

Postoperative Analgesic Effects of Dexmedetomidine Added to Bupivacaine for Transversus Abdominis Plane Block for Lower Abdominal Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02064530
• Other study ID #: 2014/37
• Status: Completed
• Phase: Phase 4
• First received: February 14, 2014
• Last updated: September 11, 2015
• Start date: February 2014
• Est. completion date: September 2015

Study information

• Verified date: September 2015
• Source: TC Erciyes University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

the aim of this study is evaluate postoperative analgesic effects of dexmedetomidine added to bupivacaine on TAP block in patients undergoing lower abdominal surgery.

Description:

TAP block is being used a method of multimodal balanced analgesia reduces postoperative pain, opioid requirement after surgery and adverse effect of opioid such as sedation, nausea vomiting and ileus. Dexmedetomidine ,an alfa-2 adrenoreceptor agonist, is being used and adjuvant capable of prolonging duration of sensory and motor block on nerve blocks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• ASA 1-2

• 18-65 aged

• patient undergoing lower abdominal surgery

Exclusion Criteria:

• chronic opioid consumption

• bupivacaine and dexmedetomidine allergies

• coagulopathy

• infection at the needle insertion side

• chronic liver and kidney disease

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pain

Intervention

Drug:
• Bupivacaine
21 ml 0.5 %bupivacaine is applied interfasially
• Dexmedetomidine
1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
• serum physiologic
21 ml serum physiologic is applied interfasially

Locations

Country	Name	City	State
Turkey	Erciyes universty	Kayseri	Melikgazi

Sponsors (1)

Lead Sponsor	Collaborator
TC Erciyes University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	opioid consumption	patient controlled analgesia	postoperative 1 day	No
Secondary	visual analog scale		postoperative 1 day	No